Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?

Antonio Munafò, Davide Arillotta, Guido Mannaioni, Fabrizio Schifano, Renato Bernardini, Giuseppina Cantarella, Antoni Camins Espuny (Editor)

Research output: Contribution to journalArticlepeer-review

49 Downloads (Pure)

Abstract

Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/”psycholitic” psychotherapy should provide significant and sustained alleviation of depressive symptoms. However, to date, there have been several study limitations (e.g., small sample sizes, blinding, limited follow-up, highly screened treatment populations) and some health/political issues, including practitioners’ experience, lack of standardized protocols, psychedelics’ legal status, ethical concerns, and potential psychological/psychopathological/medical untoward effects. The focus here is on a range of clinical and methodological issues, also aiming at outlining some possible suggestions. We are confident that newer evidence, more precise protocols, and eventual reclassification policies may allow a better understanding of the real potential of psilocybin as a transdiagnostic therapeutic molecule.
Original languageEnglish
Article number68
Pages (from-to)1-11
Number of pages11
JournalPharmaceuticals
Volume16
Issue number1
DOIs
Publication statusPublished - 31 Dec 2022

Keywords

  • Opinion
  • psilocybin
  • depression
  • clinical trials
  • methodological issues
  • ethical concerns

Fingerprint

Dive into the research topics of 'Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?'. Together they form a unique fingerprint.

Cite this